eligibility_summary
Include: adults ≥18 with consent, ECOG 0–2, confirmed CD20+ lymphoma refractory to anthracycline+anti‑CD20, eligible for commercial anti‑CD19 CAR‑T, measurable FDG‑avid lesion, adequate labs, prior toxicities resolved, contraception. Exclude: no consent, solid‑organ transplant, CNS lymphoma, major autoimmune disease or immunosuppression (exceptions incl. low‑dose steroids), other active cancer, significant CV/pulmonary disease, active HBV/HCV/HIV/serious infection, seizures, recent live vaccine, pregnancy, unsafe conditions.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase IIa, single-arm study in relapsed/refractory large B‑cell lymphomas testing: 1) Epcoritamab (GEN3013), a subcutaneous bispecific T‑cell engager (antibody) binding CD3 on endogenous T cells and CD20 on B cells to form an immune synapse, activate TCR/CD3 signaling, and induce T‑cell–mediated cytotoxicity, given in step-up doses as bridging pre–CAR‑T and post–CAR‑T for residual disease. 2) Commercial anti‑CD19 CAR‑T cells (axi‑cel [CD28/CD3ζ], tisa‑cel or liso‑cel [4‑1BB/CD3ζ])—autologous genetically engineered T cells recognizing CD19 to kill B cells via CAR signaling. Targets: malignant B cells expressing CD20 and/or CD19. Key pathways/cells: T cells (CD3 activation), CAR co‑stimulation (CD28 or 4‑1BB) plus CD3ζ, cytotoxic effector pathways, aiming to debulk disease, prevent antigen escape, and deepen responses.